Is ARE a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for Alexandria Real Estate Equities (ARE) rests on Mega-campus concentration: Alexandria is concentrating capital in large, amenity-rich campuses in the deepest research clusters, betting that top-tier tenants consolidate into the best locations. Revenue (TTM) is ~$2.7B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The near-term risk is a weak leasing environment: occupancy fell to roughly 87.7% in early 2026 amid biotech funding pressure, known lease expirations, and new lab supply, and the first quarter saw no public-biotech lease signings for the first time in company history. Whether ARE is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Alexandria Real Estate Equities is a real estate investment trust that pioneered the life-science real estate niche, building and operating collaborative lab and office campuses in top research clusters such as Boston/Cambridge, San Francisco, San Diego, Seattle, Maryland, and the Research Triangle. Its tenants are biotech firms, large pharmaceutical companies, medical-device makers, academic and government research institutions, and venture-backed startups, which lease specialized lab space that is expensive to build and hard to replicate. As a REIT, Alexandria distributes most of its taxable income as dividends and earns returns through rent, development of new campuses, and its strategic venture investments in the life-science ecosystem. The investment picture in 2026 is defined by a tough operating backdrop. A slowdown in biotech funding and a wave of new lab supply has pushed occupancy down and pressured leasing, with Alexandria reporting an unusually weak first quarter that included no public-biotech lease signings. Management has responded by focusing on its highest-quality mega-campuses, selling non-core assets, and reaffirming full-year funds-from-operations (FFO) guidance. The stock trades at a low multiple of FFO with a mid-single-digit dividend yield, so the debate centers on whether the life-science leasing cycle recovers before vacancy and debt weigh further on cash flow.
What's the case for buying ARE?
1. Mega-campus concentration
Alexandria is concentrating capital in large, amenity-rich campuses in the deepest research clusters, betting that top-tier tenants consolidate into the best locations. These flagship assets command higher rents and retention, which can support cash flow even when the broader lab market is soft.
2. Development and recycling pipeline
The company has a multi-year development and redevelopment pipeline that can add pre-leased space and grow rental income over time. It is also selling non-core properties and partial interests to fund construction and reduce reliance on external capital.
3. High, covered dividend
ARE pays a quarterly common dividend (raised to $0.72 per share for 2026) that consumes only part of its FFO, leaving retained cash flow to reinvest. The mid-single-digit yield is a core part of the total-return case for income-oriented holders.
4. Long-term life-science demand
Structural drivers such as aging populations, biotech innovation, and drug-development spending underpin long-run demand for specialized lab space. Alexandria's decades of tenant relationships and its venture-investing arm give it a window into that ecosystem.
What are the risks to ARE?
The near-term risk is a weak leasing environment: occupancy fell to roughly 87.7% in early 2026 amid biotech funding pressure, known lease expirations, and new lab supply, and the first quarter saw no public-biotech lease signings for the first time in company history. Rising vacancy, tenant credit stress among cash-burning biotechs, and mark-to-market rent risk could pressure FFO if the cycle does not recover. As a capital-intensive REIT, Alexandria carries meaningful debt, so higher-for-longer interest rates raise refinancing and development costs. Concentration in a single property type means a prolonged life-science downturn would hit it harder than a diversified landlord. Any dividend adjustment or further asset sales at depressed prices would also weigh on sentiment.
How is ARE valued? (as of July 2026)
Snapshot for ARE as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$2.7B
- Q1 2026 revenue: ~$671M
- FFO per share (2026 guidance midpoint): ~$6.40
- Q1 2026 adjusted FFO per share: ~$1.73
- Price / FFO: ~8x
- Market cap: ~$8.6B
For a REIT like Alexandria, FFO is the key earnings measure rather than GAAP EPS or P/E, because it adds back large non-cash property depreciation. At a high-single-digit multiple of guided 2026 FFO, ARE trades well below its historical range, reflecting market concern about occupancy and the life-science leasing cycle. The low multiple pairs with a mid-single-digit dividend yield.
How do you decide if ARE is a buy?
Rather than asking whether ARE is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold ARE indirectly through an index or sector ETF before adding more.
For the full picture, see the ARE stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ARE against your real portfolio and see your actual exposure before deciding.
The bottom line on ARE
The bottom line: Alexandria Real Estate Equities's story right now is Mega-campus concentration, with revenue (ttm) at ~$2.7B. If you believe that narrative continues, the call is about sizing ARE sensibly and checking overlap with what you own; if you doubt it (the risk: the near-term risk is a weak leasing environment: occupancy fell to roughly 87.7% in early 2026 amid biotech funding pressure, known lease expirations, and new lab supply, and the first quarter saw no public-biotech lease signings for the first time in company history.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
More on ARE
- ARE stock guide (what the company does, ETFs that hold it, similar stocks, and the themes it fits)
- ARE stock forecast (the drivers and risks shaping the outlook)
- Does ARE pay a dividend?
Build a basket around ARE with Walnut
Use Alexandria Real Estate Equities as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is ARE a good stock to buy right now?
+
The case for Alexandria Real Estate Equities right now is Mega-campus concentration, with revenue (ttm) at ~$2.7B. If you believe that thesis holds, ARE is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the near-term risk is a weak leasing environment: occupancy fell to roughly 87.7% in early 2026 amid biotech funding pressure, known lease expirations, and new lab supply, and the first quarter saw no public-biotech lease signings for the first time in company history. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Alexandria Real Estate Equities do?
+
Alexandria Real Estate Equities is a real estate investment trust that pioneered the life-science real estate niche, building and operating collaborative lab and office campuses in
What are the main risks of ARE?
+
The near-term risk is a weak leasing environment: occupancy fell to roughly 87.7% in early 2026 amid biotech funding pressure, known lease expirations, and new lab supply, and the first quarter saw no public-biotech lease signings for the first time in company history. Rising vacancy, tenant credit stress among cash-burning biotechs, and mark-to-market rent risk could pressure FFO if the cycle does not recover. As a capital-intensive REIT, Alexandria carries meaningful debt, so higher-for-longer interest rates raise refinancing and development costs. Concentration in a single property type means a prolonged life-science downturn would hit it harder than a diversified landlord. Any dividend adjustment or further asset sales at depressed prices would also weigh on sentiment.
What does Alexandria Real Estate Equities do?
+
It is a REIT that owns, develops, and leases laboratory and office campuses to life-science tenants, including biotech, pharmaceutical, medical-device, academic, and government research organizations, concentrated in leading US research clusters.
Is ARE a REIT, and what does that mean for investors?
+
Yes. As a real estate investment trust, Alexandria must distribute most of its taxable income to shareholders, which supports a relatively high dividend. REIT dividends are often taxed differently from qualified dividends, so holding in a tax-advantaged account can matter.
Why should I look at FFO instead of P/E for ARE?
+
REITs carry large non-cash depreciation charges that depress GAAP earnings, so funds from operations (FFO) better reflects cash-generating ability. Alexandria guided 2026 FFO per share to roughly $6.40 at the midpoint.
What is Alexandria's dividend?
+
The company declared a quarterly common dividend of $0.72 per share for 2026, which annualizes to about $2.88 and equates to a mid-single-digit yield at recent prices. The payout is covered by FFO, leaving retained cash for reinvestment.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell ARE; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.